Trial Profile
A Multi-Centre, Single Arm, Phase 2 Trial of Pembrolizumab in Treatment Naïve Patients With Poor-Prognosis Carcinoma of Unknown Primary Site
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Sep 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 08 Sep 2023 Status changed from recruiting to active, no longer recruiting.
- 21 Mar 2023 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.
- 16 Feb 2023 Planned primary completion date changed from 30 Dec 2022 to 30 Dec 2023.